Foundation Capital led the round and was joined by Lanza techVentures, both existing investors.
Guido Lanza, president and CEO of Numerate, said: “This investment will help support our business model of partnering with biotechnology and pharmaceutical companies while building on our drug design platform that provides compounds with the best chance of succeeding in the lab, clinic and marketplace.”